Clinical Trial Update: HB1801 Combined Treatment of HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

HB1801 is a Phase 2 study evaluating a combined treatment for HER2-positive breast cancer, with the trial currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HB1801

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING